All In Biotech

NDA 022100 · Cosette

Azor

Amlodipine Besylate, Olmesartan Medoxomil · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 2, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Sep 26, 2007

Approved uses

2

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

2,511

1,462 serious, 91 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue amlodipine besylate and olmesartan medoxomil as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus ( 5.1 , 8.1 ). WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue amlodipine besylate and olmesartan medoxomil as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).

What it is approved for

From the label in effect Apr 28, 2026.

Amlodipine besylate and olmesartan medoxomil is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine besylate and olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased...

Mechanism: Amlodipine besylate and olmesartan medoxomil is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of amlodipine besylate and olmesartan medoxomil inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, and the olmesartan medoxomil component of amlodipine besylate and olmesartan medoxomil blocks the vasoconstrictor effects of angiotensin II. Amlodipine ....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • AZOR · AMLODIPINE BESYLATE EQ 5MG BASE; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
  • AZOR · AMLODIPINE BESYLATE EQ 10MG BASE; OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
  • AZOR · AMLODIPINE BESYLATE EQ 5MG BASE; OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
  • AZOR · AMLODIPINE BESYLATE EQ 10MG BASE; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sprue-like enteropathy327
  • gastrooesophageal reflux disease210
  • diarrhoea183
  • dizziness180
  • acute kidney injury170
  • weight decreased166
  • drug ineffective147
  • nausea138
  • haemorrhoids133
  • chronic kidney disease126
  • constipation116
  • fatigue111

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20072
200836
2009101
2010164
2011176
2012205
2013117
2014113
2015379
2016333
2017239
2018287
2019134
202072
202142
202221
202322
202422
202527
202619

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azor (Amlodipine Bes/Olmesartan Med)

2024 spending

$2.9M

Beneficiaries

720

3,507 claims

Per beneficiary

$3,986

$13.84 per unit

View as table
YearSpending
2020$4,911,912
2021$4,352,589
2022$3,803,803
2023$3,345,694
2024$2,869,756

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,808 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.